Latest Updates
|
Second Quarter 2010 Marketed Drug
Updates and Additions
|
Brand Name
|
Generic Name
|
Other Designation
|
|
Gemcitabine |
|
|
Oxaliplatin |
|
|
Thalidomide |
|
Abraxane |
Nanoparticle albumin-bound (nab) paclitaxel, paclitaxel albumin bound (PAB) |
ABI-007 |
Afinitor (cancer), Certican (immunosuppression-ROW), Zortress (immunosuppression-USA) |
Everolimus |
RAD001, RAD001C |
Aldara |
Imiquimod |
|
Arzerra |
Ofatumumab |
HuMax-CD20, GSK1841157 |
Avastin |
Bevacizumab |
rhuMAb-VEGF, NSC-704865, R435, RG435 |
Celebrex (formerly known as Celebra) |
Celecoxib |
SC-236, SC-58635 |
Ceplene (formerly Maxamine and EpiLeukin) |
Histamine dihydrochloride |
|
Eloxatin, Eloxatine, Elplat (Japan) |
Oxaliplatin (L-OHP) |
1670RB, RP 54780 |
Endu, Endostar |
|
|
Erbitux |
Cetuximab |
IMC-C225 |
Feraheme |
Ferumoxytol |
Code 7228 |
Folotyn |
Pralatrexate |
PDX |
Gemzar |
Gemcitabine |
|
Iressa |
Gefitinib |
ZD1839, ZD-1839 |
Jevtana |
Cabazitaxel |
XRP6258, XRP 6258 (formerly RPR116258, RPR116258A, 116258) |
Mylotarg |
Gemtuzumab ozogamicin |
CMA-676, CDP771 |
Nexavar |
Sorafenib tosylate |
BAY 43-9006 |
Nikidess, Aromasin |
Exemestane |
FCE 24304 |
Polyphenon E Ointment, Veregen |
|
|
Provenge |
Sipuleucel-T |
Antigen-presenting cells 8015 (APC8015) |
Revlimid (formerly Revimid), Lenalidomide-Celgene Europe |
Lenalidomide |
CDC501, CDC-501, CDC-5013, CC5013, CC-5013 |
Rituxan (USA), MabThera (Europe) |
Rituximab |
IDEC-C2B8, RG105 |
Sutent |
Sunitinib malate |
SU011248, SU11248, SU-11248 |
Tarceva |
Erlotinib |
CP 358774, OSI-774, R1415, RG1415, NSC 718781 |
Tasigna |
Nilotinib |
AMN107, AMN-107 |
Valstar, Valtaxin (Canada) |
Valrubicin |
AD32 |
Vantas |
Histrelin |
Formerly RL0903 |
Vidaza |
Azacitidine (AzaC), 5-azacytidine |
NSC-102816 |
Xeloda |
Capecitabine |
Ro 09-1978, RG340 |
Yondelis |
Trabectedin |
Ecteinascidin 743, ET-743, NSC 648766 |
|
NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE: 1-949-830-0448 FAX: 1-949-830-0887
INFO@NEWMEDINC.COM
|